Inquiry
Form loading...

Needle-free Delivery as a Drug Development and Lifecycle Strategy

Designed for Sustainable Self-Administration

•Enables patient-centric self-injection without changing drug formulation

•Supports long-term treatment adherence in chronic and preventive therapies

Suitable for home-use scenarios under established human factors frameworks

Aligned with Clinical and Risk Management Considerations

•Eliminates needle-related handling and disposal risks

•Reduces variability associated with needle insertion and withdrawal

•Designed to minimize localized tissue stress under controlled delivery profiles

A Differentiation Layer Without Reformulation

•Enables product differentiation at the device and delivery level

•Preserves existing drug substance and drug product strategy

Supports lifecycle extension and market-specific variant positioning

Drug-Specific Delivery Evidence

Published data supporting needle-free delivery across drug categories:

Acute therapies → rapid dispersion profiles supporting fast onset

Sustained-release formulations → uniform distribution reducing local stress

Nucleic acid drugs (mRNA) → micro-jet delivery enhancing cellular uptake

Explore Scientific Publications
010203
slide1

Design Capability Anchored in Human Factors Engineering

A structured design approach translating human factors principles into manufacturable medical devices.

Design Rationale Inspired by Natural Forms

0102
Product Finder1

Independent IP Portfolio Supporting Secure Collaboration

With an independent patent portfolio covering core mechanisms, device architecture, and key components, our needle-free technology provides a stable IP foundation for licensing, co-development, and long-term collaboration.

How to Engage with Quinovare

A structured entry path for pharmaceutical and biotech collaboration.

Typical engagement pathways include:

• Device evaluation and technical discussion under NDA

• Platform adaptation for specific drug formulations and delivery needs therapies

Co-development of combination products for global registration

• Licensing or regional collaboration based on defined scopes

NEach engagement follows a staged process aligned with pharmaceutical development and regulatory requirements.

NewsNews and Information

010203